Blood markers for bleeding in leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at markers in the blood to understand why low red blood cell counts (anemia) can cause bleeding problems in people with certain leukemias. It may help find better ways to treat or prevent bleeding during early chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are currently in the hospital
- You have acute myeloid leukemia or acute lymphocytic leukemia
- You started your first chemotherapy treatment less than 5 days ago
- Your hemoglobin level is below 130 g/L (a sign of low red blood cells)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new score (SiAML) to predict bleeding and blood clot risks in people newly diagnosed with acute leukemia. It aims to help doctors better manage these risks compared to current tests.
This study looks at what leads to specific blood cancers and related blood disorders. If you have one of the listed conditions (or are being evaluated for it), you may be asked to join research that helps doctors understand why these illnesses happen.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study compares two different strategies for when to give red blood cell transfusions to people receiving intensive chemotherapy or stem cell transplant for high-grade myeloid neoplasms, AML or B-ALL. The goal is to see which approach better improves quality of life and daily function.
This study looks at blood clotting problems in children with acute lymphoblastic leukemia (ALL) who are being treated with the ALLTogether1 protocol. It aims to understand how the disease and its treatment affect clotting, which could help improve care.
This study looks at how blood counts and clotting change in adults newly diagnosed with acute myeloid leukemia (AML) who receive a strong type of chemotherapy. It aims to better understand how to manage these patients during treatment.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.